PHOENIXBIO CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 484 JPY | -1.63% |
|
-1.02% | +3.86% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,987 | 2,093 | 1,646 | 2,026 | 1,733 | 2,235 |
| Enterprise Value (EV) 1 | 2,186 | 1,510 | 1,185 | 1,736 | 1,445 | 1,809 |
| P/E ratio | -11 x | -7.03 x | -3.96 x | -8.37 x | -4.47 x | 6.32 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.31 x | 1.7 x | 1.26 x | 2 x | 1.31 x | 1.05 x |
| EV / Revenue | 2.42 x | 1.23 x | 0.9 x | 1.71 x | 1.09 x | 0.85 x |
| EV / EBITDA | -8.96 x | -6.04 x | -18.8 x | -7.82 x | -17.6 x | 3.4 x |
| EV / FCF | -11.3 x | -9.83 x | -64.1 x | -8.04 x | -32.1 x | 22 x |
| FCF Yield | -8.84% | -10.2% | -1.56% | -12.4% | -3.11% | 4.55% |
| Price to Book | 1.61 x | 1.36 x | 1.42 x | 1.85 x | 2.09 x | 1.48 x |
| Nbr of stocks (in thousands) | 2,906 | 2,923 | 2,934 | 3,288 | 3,307 | 3,634 |
| Reference price 2 | 1,028 | 716.0 | 561.0 | 616.0 | 524.0 | 615.0 |
| Announcement Date | 29/06/18 | 28/06/19 | 26/06/20 | 25/06/21 | 29/06/22 | 28/06/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 902 | 1,228 | 1,310 | 1,013 | 1,324 | 2,124 |
| EBITDA 1 | -244 | -250 | -63 | -222 | -82 | 532 |
| EBIT 1 | -268 | -312 | -147 | -277 | -168 | 509 |
| Operating Margin | -29.71% | -25.41% | -11.22% | -27.34% | -12.69% | 23.96% |
| Earnings before Tax (EBT) 1 | -267 | -295 | -416 | -224 | -392 | 510 |
| Net income 1 | -270 | -297 | -415 | -238 | -387 | 493 |
| Net margin | -29.93% | -24.19% | -31.68% | -23.49% | -29.23% | 23.21% |
| EPS 2 | -93.08 | -101.8 | -141.6 | -73.60 | -117.2 | 97.29 |
| Free Cash Flow 1 | -193.1 | -153.6 | -18.5 | -215.8 | -45 | 82.25 |
| FCF margin | -21.41% | -12.51% | -1.41% | -21.3% | -3.4% | 3.87% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 15.46% |
| FCF Conversion (Net income) | - | - | - | - | - | 16.68% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 29/06/18 | 28/06/19 | 26/06/20 | 25/06/21 | 29/06/22 | 28/06/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 S1 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 521 | 301 | 637 | 296 | 445 | 1,135 | 525 | 439 | 881 | 447 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -165 | -288 | -133 | -39 | 89 | 367 | 97 | 7 | -5 | 35 |
| Operating Margin | -31.67% | -95.68% | -20.88% | -13.18% | 20% | 32.33% | 18.48% | 1.59% | -0.57% | 7.83% |
| Earnings before Tax (EBT) 1 | -155 | -265 | -128 | -30 | 113 | 403 | 43 | 47 | 63 | -14 |
| Net income 1 | -156 | -267 | -130 | -31 | 103 | 356 | 37 | 42 | 27 | -13 |
| Net margin | -29.94% | -88.7% | -20.41% | -10.47% | 23.15% | 31.37% | 7.05% | 9.57% | 3.06% | -2.91% |
| EPS 2 | -53.54 | -83.98 | -39.59 | -9.420 | 31.26 | 107.6 | 10.05 | 11.59 | 7.530 | -3.640 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 14/11/19 | 13/11/20 | 12/11/21 | 14/02/22 | 12/08/22 | 14/11/22 | 14/02/23 | 14/08/23 | 14/11/23 | 14/02/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 801 | 583 | 461 | 290 | 288 | 426 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -193 | -154 | -18.5 | -216 | -45 | 82.3 |
| ROE (net income / shareholders' equity) | -13.6% | -17.5% | -30.7% | -21.1% | -40.3% | 42.1% |
| ROA (Net income/ Total Assets) | -7.36% | -9.57% | -3.92% | -6.53% | -4.38% | 12% |
| Assets 1 | 3,670 | 3,103 | 10,590 | 3,643 | 8,838 | 4,105 |
| Book Value Per Share 2 | 639.0 | 528.0 | 396.0 | 332.0 | 250.0 | 417.0 |
| Cash Flow per Share 2 | 321.0 | 224.0 | 605.0 | 404.0 | 401.0 | 428.0 |
| Capex 1 | 5 | 64 | 30 | 181 | 6 | 7 |
| Capex / Sales | 0.55% | 5.21% | 2.29% | 17.87% | 0.45% | 0.33% |
| Announcement Date | 29/06/18 | 28/06/19 | 26/06/20 | 25/06/21 | 29/06/22 | 28/06/23 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +3.86% | 12.63M | |
| +46.03% | 55.66B | |
| -7.53% | 38.98B | |
| +35.88% | 38.8B | |
| -9.38% | 27.32B | |
| +12.31% | 26.29B | |
| -16.38% | 20.25B | |
| +30.79% | 12.76B | |
| +28.57% | 12.18B | |
| -0.36% | 12.12B |
- Stock Market
- Equities
- 6190 Stock
- Financials PhoenixBio Co., Ltd.
